Cargando…
Sponsors’ and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials
BACKGROUND/AIMS: The Food and Drug Administration’s final rule on investigational new drug application safety reporting, effective from 28 March 2011, clarified the reporting requirements for serious and unexpected suspected adverse reactions occurring in clinical trials. The Clinical Trials Transfo...
Autores principales: | Perez, Raymond, Archdeacon, Patrick, Roach, Nancy, Goodwin, Robert, Jarow, Jonathan, Stuccio, Nina, Forrest, Annemarie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560478/ https://www.ncbi.nlm.nih.gov/pubmed/28345368 http://dx.doi.org/10.1177/1740774517700640 |
Ejemplares similares
-
Industry-sponsored economic studies in oncology vs studies sponsored by nonprofit organisations
por: Hartmann, M, et al.
Publicado: (2003) -
Clinical Trial Electronic Portals for Expedited Safety Reporting: Recommendations from the Clinical Trials Transformation Initiative Investigational New Drug Safety Advancement Project
por: Perez, Raymond P, et al.
Publicado: (2016) -
Optimizing Expedited Safety Reporting for Drugs and Biologics Subject to an
Investigational New Drug Application
por: Archdeacon, Patrick, et al.
Publicado: (2013) -
Regulatory Framework for Academic Investigator-Sponsored Investigational New Drug Development of Cell and Gene Therapies in the USA
por: Dasgupta, Anindya, et al.
Publicado: (2021) -
ASCO-Sponsored Oncology Student Interest Groups in the World
por: Anampa-Guzmán, Andrea, et al.
Publicado: (2021)